| Assessment Status | Assessment Process Complete |
| HTA ID | - |
| Drug | Midostaurin |
| Brand | Rydapt® |
| Indication | Is indicated in combination with standard daunorubicin and cytarabine induction and high dose cytarabine consolidation chemotherapy, and for patients in complete response followed by midostaurin single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia (AML) who are FLT3 mutation positive. |
| Assessment Process | |
| Rapid review commissioned | 13/08/2018 |
| Rapid review completed | 10/09/2018 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of midostaurin compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 19/09/2018 |
| Pre-submission consultation with Applicant | 15/10/2018 |
| Full submission received from Applicant | 20/12/2018 |
| Preliminary review sent to Applicant | 25/06/2019 |
| NCPE assessment re-commenced | 12/08/2019 |
| Factual accuracy sent to Applicant | 24/10/2019 |
| NCPE assessment re-commenced | 11/11/2019 |
| NCPE assessment completed | 04/12/2019 |
| NCPE assessment outcome | The NCPE recommends midostaurin (Rydapt®) for AML not be considered for reimbursement unless cost effectiveness can be improved relative to existing treatments. * |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations October 2021
